Abstract
The aim of the study was to decipher the relationship between serum uric acid (SUA) and glycated hemoglobin A1c (HbA1c) or fasting plasma glucose (FPG) in both type 2 diabetes mellitus (T2DM) patients and normal subjects. A total of 2,250 unrelated T2DM patients and 4,420 Han Chinese subjects from a physical examination population were recruited for this study. In T2DM patients SUA levels were negatively correlated with HbA1c (rs = −0.109, P = 0.000) and 2 h plasma glucose levels (rs = −0.178, P = 0.000). In the physical examination population, SUA levels were inversely correlated with HbA1c (rs = −0.175, P = 0.000) and FPG (rs = −0.131, P = 0.009) in T2DM patients but positively correlated with HbA1c (rs = 0.040, P = 0.012) and FPG (rs = 0.084, P = 0.000) in normal-glucose subjects. Multivariate analyses showed that HbA1c was significantly negatively associated with HUA both in T2DM patients (OR = 0.872, 95% CI: 0.790~0.963) and in the physical examination T2DM patients (OR = 0.722, 95% CI: 0.539~0.968). Genetic association studies in T2DM patients showed that alleles of two glucose-uric acid transporter genes, ABCG2 and SLC2A9 were significantly associated with SUA levels (P < 0.05). SUA level is inversely correlated with HbA1c in T2DM patients but positively correlated with HbA1c in normal-glucose subjects. The reverse transporting of uric acid and glucose in renal tubules might be accounted for these associations.
Serum uric acid (SUA) is the final oxidation product of purine metabolism in circulation. Hyperuricemia (HUA), or elevated SUA levels, has been considered not only an independent risk factor for cardiovascular diseases (CVDs) but also a factor in the development of metabolic diseases1. Diseases associated with HUA in humans include hypertension, chronic kidney disease, and type 2 diabetes mellitus (T2DM). Interestingly, low SUA levels have also been found to be associated with diseases of neurological origin, such as Parkinson’s disease, multiple sclerosis, and Alzheimer’s disease2. Elevated SUA levels (i.e., HUA) have been associated with MetS and CVD morbidity and mortality. HUA and MetS were both associated with adverse renal outcome.
Hemoglobin A1c (HbA1c) has been recommended by the American Diabetes Association as an optional assay for the diagnosis of T2DM and also for identifying individuals at increased risk of T2DM. HbA1c reflects an average blood glucose level over the past 3 months. Thus, HbA1c levels provide a longer-term picture of blood glucose status as an exposure variable. However, the relationship between SUA and HbA1c/FPG was not completely consistent: many studies showed a positive correlation between SUA and fasting plasma glucose (FPG) while others suggested an inverse relationship3,4,5. Recent studies (including ours) found that uric acid-hexose transporters account for significant amount of genetic variance of SUA6,7,8, thus, we suspected that the SUA-FPG paradox actually is a result of glucose-uric acid coupled transporting. Instead of a cross section study for SUA-HbA1c/FPG in T2DM patients, it is necessary to evaluate the dynamic change of the SUA and FPG levels in different stages of hyperglycemia.
In this study, we examined the correlation between SUA and HbA1c/FPG levels in T2DM patients and subjects with normal FPG. Besides, we also considered the influence of renal function (measured by estimated glomerular filtration rates (eGFR)) on the SUA-HbA1c correlation. Interestingly, we found the SUA level seems coupled with FPG and HbA1c in both T2DM and normal individuals, although the correlations were not in the same direction. SUA levels changed with FPG, however, the SUA-FPG coupling vanished in T2DM patients with impaired renal function. We also found genotype-phenotype associations among two hexose-uric acid transporter gene polymorphisms and SUA. These results suggested a plausible mechanism that the glucose-SUA coupled transportation may account for the dynamic SUA level change during different stages of T2DM.
Results
Baseline characteristics
The T2DM patients comprised 1,218 (54.1%) men (median (±Q) 57.00 ± 14.00 years of age) and 1,032 (45.9%) women (61.00 ± 15.00 years of age). In the physical examination population, 2550 (71.9%) men (62.87 ± 15.62 years of age) and 999 (28.1%) women (61.10 ± 15.62 years of age) had normal glucose, and 722 (82.9%men (69.62 ± 12.92 years of age) and 149 (17.1%) women (75.79 ± 22.78 years of age) were T2DM. HUA prevalence in the physical examination population was 16.20% (men, 17.67%; women, 12.02%) and was more frequent in men (χ2 = 19.943, P = 0.000). HUA prevalence in the T2DM patients was 17.25% (men, 14.86%; women, 20.06%) and was more frequent in women (χ2 = 10.576, P = 0.001).
In the T2DM patients (Table 1), HUA and normal subjects did not significantly differ in DBP (P = 0.298), ALT (P = 0.388), GGT (P = 0.173), HDL (P = 0.110), LDL (P = 0.415),FBG (P = 0.601), or plasma glucose 2 h after an oral glucose tolerance test (P2hG; P = 0.262), Furthermore, between the T2DM patients with normal SUA and HUA, a gradual and significant increasing trend was observed in age (P = 0.001), BMI (P = 0.000),SBP (P = 0.000), AST (P = 0.000), BUN (P = 0.000), serum CR (P = 0.000), SUA (P = 0.000), TC (P = 0.007), TG (P = 0.000), VLDL (P = 0.000), FINS (P = 0.000), P2INS (P = 0.000), and HOMA-IR (P = 0.000), but a decreasing trend in eGFR (P = 0.000) and glycated HbA1c (P = 0.001).
Table 1. Basic characteristics of the subjects with type 2 diabetes mellitus (M ± Q).
| Characteristic | Total | Normal | HUA | Zvalue | Pvalue |
|---|---|---|---|---|---|
| N (male/female) | 2250 (1218/1032) | 1862 (1037/825) | 388 (181/207) | 10.576 | 0.001 |
| Age (years) | 59.00 ± 15.00 | 58.00 ± 14.00 | 61.00 ± 19.00 | −3.274 | 0.001 |
| BMI (kg/m2) | 25.93 ± 4.85 | 25.71 ± 4.66 | 27.10 ± 5.10 | −5.881 | 0.000 |
| SBP (mmHg) | 130.00 ± 15.00 | 130.00 ± 15.00 | 130.00 ± 20.00 | −4.347 | 0.000 |
| DBP (mmHg) | 80.00 ± 10.00 | 80.00 ± 10.00 | 80.00 ± 10.00 | −1.040 | 0.298 |
| ALT (IU/l) | 20.00 ± 15.15 | 20.00 ± 14.73 | 18.95 ± 16.60 | −0.862 | 0.388 |
| AST (IU/l) | 18.40 ± 9.00 | 18.00 ± 8.72 | 19.60 ± 9.50 | −3.726 | 0.000 |
| GGT (IU/l) | 24.60 ± 0.70 | 24.00 ± 20.40 | 25.50 ± 21.45 | −1.362 | 0.173 |
| eGFR (ml/min per 1.73 m2) | 97.38 ± 45.21 | 100.27 ± 43.41 | 74.76 ± 48.63 | −11.774 | 0.000 |
| BUN (mmol/l) | 5.70 ± 2.39 | 5.60 ± 2.20 | 6.91 ± 3.36 | −10.592 | 0.000 |
| SCR (μmol/l) | 69.60 ± 29.65 | 67.50 ± 26.40 | 86.00 ± 43.70 | −11.255 | 0.000 |
| SUA (μmol/l) | 302.20 ± 119.70 | 283.80 ± 95.30 | 441.15 ± 78.88 | −28.760 | 0.000 |
| TG (mmol/l) | 1.63 ± 1.22 | 1.56 ± 1.14 | 1.95 ± 1.45 | −6.250 | 0.000 |
| TC (mmol/l) | 5.14 ± 1.56 | 5.13 ± 1.49 | 5.28 ± 1.88 | −2.707 | 0.007 |
| HDL (mmol/l) | 1.30 ± 0.50 | 1.30 ± 0.40 | 1.30 ± 0.40 | −1.596 | 0.110 |
| LDL (mmol/l) | 3.13 ± 1.31 | 3.13 ± 1.26 | 3.16 ± 1.42 | −0.815 | 0.415 |
| VLDL (mmol/l) | 0.60 ± 0.45 | 0.59 ± 0.40 | 0.66 ± 0.54 | −4.233 | 0.000 |
| HbA1c (%) | 7.70 ± 2.40 | 7.70 ± 2.40 | 7.40 ± 1.90 | −3.225 | 0.001 |
| HbA1c (mmol/mol) | 64.23 ± 19.72 | 64.57 ± 19.79 | 60.63 ± 17.30 | 3.341 | 0.001 |
| FPG (mmol/l) | 7.70 ± 2.98 | 7.70 ± 3.00 | 7.70 ± 2.78 | −0.522 | 0.601 |
| P2hG (mmol/l) | 18.10 ± 5.95 | 18.10 ± 5.85 | 17.50 ± 6.60 | −1.121 | 0.262 |
| FINS (mIU/l) | 8.97 ± 9.90 | 8.63 ± 9.58 | 12.70 ± 10.45 | −4.419 | 0.000 |
| P2INS (mIU/l) | 35.80 ± 41.95 | 35.00 ± 39.55 | 46.10 ± 66.41 | −3.547 | 0.000 |
| HOMA-IR | 2.96 ± 3.63 | 2.72 ± 3.61 | 4.21 ± 3.73 | −3.624 | 0.000 |
| duration of diabetes (years) | 9.00 ± 11.00 | 9.00 ± 11.00 | 10.00 ± 11.00 | −3.667 | 0.000 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; SCR, serum creatinine; SUA, serum uric acid; TG, triglycerides; TC, total cholesterol; HDL, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein cholesterol; VLDL,very low-density lipoprotein; HbA1c, glyated hemoglobin; FPG, fasting plasma glucose; P2hG, plasma glucose 120 min after an oral glucose tolerance test; FINS, fasting serum insulin; P2INS, serum insulin 120 min after an oral glucose tolerance test; HOMA-IR, homeostasis model assessment of insulin resistance.
In normal-glucose subjects in the physical examination population (Table 2), a gradual and significant increasing trend was observed from normal to HUA subjects in age (P = 0.001), BMI (P = 0.000), SBP (P = 0.000), DBP (P = 0.019), BUN (P = 0.000), serum CR (P = 0.000), SUA (P = 0.000), FBG (P = 0.001), glycated HbA1c (P = 0.000), and TG (P = 0.000) but a decreasing trend in eGFR (P = 0.000) and HDL (P = 0.000).
Table 2. Basic characteristics of the physical examination population.
| Characteristic |
Normal glucose |
T2DM |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Normal SUA | HUA | Z | P | Total | Normal SUA | HUA | Z | P | |
| N (male/female) | 3549 (2550/999) | 2993 (2098/895) | 556 (452/104) | 20.072 | 0.000 | 871 (722/149) | 711 (596/115) | 160 (126/34) | 2.373 | 0.123 |
| Age (years) | 63.10 ± 25.62 | 63.10 ± 25.02 | 63.70 ± 28.02 | −2.328 | 0.000 | 72.69 ± 24.42 | 73.71 ± 24.42 | 68.10 ± 23.00 | −2.025 | 0.025 |
| eGFR (ml/min per 1.73 m2) | 85.77 ± 21.43 | 87.21 ± 20.72 | 76.48 ± 24.13 | −14.683 | 0.000 | 84.63 ± 20.46 | 85.60 ± 19.50 | 78.35 ± 22.85 | −3.501 | 0.000 |
| BMI (kg/m2) | 24.59 ± 4.24 | 24.39 ± 4.14 | 25.91 ± 4.37 | −9.684 | 0.000 | 26.06 ± 3.84 | 25.78 ± 4.01 | 27.08 ± 3.97 | −3.090 | 0.002 |
| SBP (mmHg) | 137.00 ± 26.00 | 136.00 ± 27.00 | 139.00 ± 25.00 | −3.526 | 0.000 | 146.00 ± 29.00 | 146.00 ± 29.00 | 146.00 ± 25.50 | −0.819 | 0.413 |
| DBP (mmHg) | 75.00 ± 18.00 | 75.00 ± 17.00 | 77.00 ± 19.00 | −2.340 | 0.019 | 77.00 ± 18.00 | 76.50 ± 18.00 | 77.50 ± 17.50 | −0.360 | 0.719 |
| BUN (mmol/l) | 5.10 ± 1.80 | 5.00 ± 1.60 | 5.50 ± 2.20 | −9.975 | 0.000 | 5.60 ± 1.90 | 5.60 ± 2.00 | 5.70 ± 1.95 | −1.009 | 0.313 |
| SCR (μmol/l) | 80.00 ± 20.00 | 78.00 ± 19.00 | 89.00 ± 24.00 | −16.753 | 0.000 | 82.00 ± 18.00 | 81.00 ± 16.00 | 87.00 ± 20.00 | −3.063 | 0.002 |
| SUA (μmol/l) | 329.00 ± 109.00 | 312.00 ± 90.00 | 451.00 ± 57.00 | −38.985 | 0.000 | 325.00 ± 105.00 | 308.00 ± 82.00 | 451.50 ± 51.50 | −12.716 | 0.000 |
| FPG (mmol/l) | 5.20 ± 0.70 | 5.20 ± 0.70 | 5.30 ± 0.80 | −3.193 | 0.001 | 7.90 ± 1.50 | 8.00 ± 1.50 | 7.50 ± 1.05 | −2.201 | 0.028 |
| HbA1c (%) | 5.70 ± 0.50 | 5.70 ± 0.50 | 5.80 ± 0.60 | −4.006 | 0.000 | 7.30 ± 1.50 | 7.30 ± 1.50 | 7.05 ± 1.38 | −2.108 | 0.031 |
| HbA1c (mmol/mol) | 39.55 ± 4.51 | 39.42 ± 4.45 | 40.21 ± 4.77 | −4.057 | 0.000 | 56.58 ± 8.74 | 57.01 ± 9.33 | 55.12 ± 8.87 | −2.336 | 0.020 |
| TG (mmol/l) | 1.22 ± 0.80 | 1.17 ± 0.74 | 1.57 ± 1.01 | −12.812 | 0.000 | 1.49 ± 1.05 | 1.38 ± 0.96 | 2.01 ± 1.60 | −5.048 | 0.000 |
| HDL (mmol/l) | 1.29 ± 0.51 | 1.32 ± 0.52 | 1.18 ± 0.44 | −9.478 | 0.000 | 1.13 ± 0.38 | 1.15 ± 0.40 | 1.08 ± 0.32 | −1.777 | 0.075 |
| a Basic characteristics of the physical examination population (men). | ||||||||||
| N (male) | 2550 | 2098 | 452 | – | – | 722 | 596 | 126 | – | – |
| Age (years) | 62.70 ± 25.62 | 63.10 ± 25.18 | 61.10 ± 27.02 | −0.074 | 0.941 | 69.12 ± 22.67 | 69.96 ± 22.62 | 61.48 ± 25.62 | −2.129 | 0.033 |
| eGFR (ml/min per 1.73 m2) | 85.89 ± 21.01 | 87.10 ± 20.29 | 78.06 ± 23.33 | −10.88 | 0.000 | 85.78 ± 21.29 | 87.14 ± 20.70 | 78.88 ± 22.36 | −5.076 | 0.000 |
| BMI (kg/m2) | 24.99 ± 4.05 | 24.76 ± 3.85 | 26.10 ± 4.12 | −7.642 | 0.000 | 25.90 ± 3.53 | 25.79 ± 3.52 | 26.64 ± 3.70 | −2.836 | 0.005 |
| SBP (mmHg) | 137.00 ± 25.00 | 137.00 ± 25.00 | 138.00 ± 23.00 | −0.877 | 0.380 | 146.00 ± 27.00 | 146.00 ± 29.00 | 144.00 ± 23.00 | −0.514 | 0.607 |
| DBP (mmHg) | 77.00 ± 17.00 | 77.00 ± 16.00 | 77.00 ± 18.00 | −1.237 | 0.216 | 78.00 ± 18.00 | 78.00 ± 19.00 | 79.00 ± 16.00 | −0.720 | 0.472 |
| BUN (mmol/l) | 5.20 ± 1.80 | 5.20 ± 1.70 | 5.60 ± 2.10 | −6.043 | 0.000 | 5.40 ± 1.80 | 5.30 ± 1.80 | 5.60 ± 1.90 | −2.080 | 0.038 |
| SCR (μmol/l) | 84.00 ± 16.00 | 83.00 ± 15.00 | 91.00 ± 23.00 | −12.09 | 0.000 | 83.00 ± 17.00 | 81.50 ± 16.00 | 89.50 ± 21.00 | −5.971 | 0.000 |
| SUA (μmol/l) | 347.00 ± 101.00 | 332.00 ± 81.00 | 457.00 ± 53.00 | −33.43 | 0.000 | 339.00 ± 107.00 | 321.00 ± 84.50 | 467.50 ± 51.75 | −17.66 | 0.000 |
| FPG (mmol/l) | 5.20 ± 0.60 | 5.20 ± 0.60 | 5.30 ± 0.60 | −2.252 | 0.026 | 6.80 ± 1.50 | 6.85 ± 1.53 | 6.80 ± 1.10 | −2.101 | 0.031 |
| HbA1c (%) | 5.70 ± 0.60 | 5.70 ± 0.50 | 5.75 ± 0.50 | −2.128 | 0.033 | 6.50 ± 1.20 | 6.60 ± 1.20 | 6.50 ± 1.03 | −2.018 | 0.041 |
| TG (mmol/l) | 1.23 ± 0.82 | 1.18 ± 0.75 | 1.51 ± 1.00 | −9.456 | 0.000 | 1.38 ± 1.01 | 1.32 ± 0.91 | 1.98 ± 1.54 | −7.404 | 0.000 |
| HDL (mmol/l) | 1.24 ± 0.43 | 1.26 ± 0.45 | 1.16 ± 0.40 | −5.945 | 0.000 | 1.13 ± 0.39 | 1.15 ± 0.38 | 1.04 ± 0.34 | −4.025 | 0.000 |
| b Basic characteristics of the physical examination population (women). | ||||||||||
| N (female) | 999 | 895 | 104 | – | – | 149 | 115 | 34 | – | – |
| Age (years) | 61.10 ± 25.62 | 60.10 ± 23.60 | 75.16 ± 25.02 | −6.091 | 0.000 | 75.75 ± 22.74 | 76.04 ± 24.00 | 74.11 ± 22.02 | −0.521 | 0.602 |
| eGFR (ml/min per 1.73 m2) | 85.59 ± 22.50 | 87.04 ± 22.05 | 69.60 ± 23.04 | −9.402 | 0.000 | 81.82 ± 24.21 | 84.65 ± 21.18 | 71.76 ± 28.92 | −3.055 | 0.002 |
| BMI (kg/m2) | 23.18 ± 3.82 | 23.05 ± 3.76 | 24.46 ± 4.97 | −3.254 | 0.001 | 25.33 ± 5.13 | 24.30 ± 4.79 | 27.47 ± 5.03 | −3.054 | 0.002 |
| SBP (mmHg) | 132.00 ± 31.00 | 130.00 ± 30.00 | 141.00 ± 30.00 | −4.855 | 0.000 | 146.00 ± 31.00 | 146.00 ± 34.00 | 144.50 ± 29.00 | −0.787 | 0.431 |
| DBP (mmHg) | 70.00 ± 15.00 | 70.00 ± 15.00 | 70.00 ± 18.50 | −0.745 | 0.456 | 71.00 ± 17.00 | 72.00 ± 16.00 | 69.00 ± 17.00 | −0.880 | 0.379 |
| BUN (mmol/l) | 4.70 ± 1.60 | 4.70 ± 1.60 | 5.50 ± 2.75 | −7.156 | 0.000 | 5.40 ± 1.83 | 5.35 ± 2.00 | 5.55 ± 1.98 | −2.223 | 0.026 |
| SCR (μmol/l) | 65.00 ± 13.00 | 64.00 ± 13.00 | 76.00 ± 21.00 | −9.380 | 0.000 | 66.00 ± 15.25 | 63.00 ± 12.00 | 73.50 ± 24.75 | −3.416 | 0.001 |
| SUA (μmol/l) | 271.00 ± 88.00 | 262.00 ± 75.00 | 392.00 ± 53.50 | −16.79 | 0.000 | 298.50 ± 95.25 | 281.00 ± 63.25 | 403.00 ± 70.75 | −8.852 | 0.000 |
| FPG (mmol/l) | 5.10 ± 0.60 | 5.10 ± 0.60 | 5.20 ± 0.60 | −2.102 | 0.039 | 6.80 ± 1.10 | 6.80 ± 1.00 | 6.70 ± 1.25 | −0.817 | 0.414 |
| HbA1c (%) | 5.70 ± 0.50 | 5.70 ± 0.40 | 5.80 ± 0.60 | −3.905 | 0.000 | 6.75 ± 1.10 | 6.75 ± 1.20 | 6.60 ± 1.10 | −2.032 | 0.040 |
| TG (mmol/l) | 1.15 ± 0.71 | 1.12 ± 0.66 | 1.48 ± 0.79 | −5.955 | 0.000 | 1.44 ± 0.86 | 1.35 ± 0.79 | 1.69 ± 1.16 | −2.090 | 0.037 |
| HDL (mmol/l) | 1.56 ± 0.55 | 1.57 ± 0.54 | 1.40 ± 0.56 | −4.061 | 0.000 | 1.33 ± 0.43 | 1.36 ± 0.46 | 1.26 ± 0.39 | −1.178 | 0.074 |
Abbreviations are as in Table 1.
In T2DM patients of physical examination population (Table 2), there was no significant difference between HUA and normal-SUA subjects in SBP (P = 0.413), DBP (P = 0.719), BUN (P = 0.313), and HDL (P = 0.075). A gradual and significant increasing trend was observed in age (0.025), BMI (P = 0.002), serum CR (P = 0.002), SUA (P = 0.000), and TG (P = 0.000) but a decreasing trend in eGFR (P = 0.000), FBG (P = 0.028), and glycated HbA1c (P = 0.031).
Correlation between characteristics and SUA
A Spearman correlation analysis was used to estimate correlation between clinical characteristics and SUA in T2DM patients and the physical examination population. SUA levels in T2DM patients were positively correlated with BMI, both SBP and DBP, renal function (serum CR, BUN), blood lipids (TG, VLDL), blood glucose, and insulin resistance index (FINS, P2INS, HOMA-IR; P-values < 0.05) and negatively correlated with HDL, glycated HbA1c, P2hG, and eGFR (P-values < 0.05) (Table 3). We found no significant correlation between SUA and age, TC, LDL, or FPG.
Table 3. Correlation analyses among serum uric acid levels and clinical characteristics in subjects with type 2 diabetes mellitus.
| Variable |
All subjects |
eGFR normal |
eGFR abnormal |
|||
|---|---|---|---|---|---|---|
| rs | P | rs | P | rs | P | |
| Age (years) | −0.014 | 0.538 | −0.119 | 0.000 | −0.092 | 0.008 |
| BMI (kg/m2) | 0.257 | 0.000 | 0.297 | 0.000 | 0.228 | 0.000 |
| SBP (mmHg) | 0.159 | 0.000 | 0.105 | 0.001 | 0.084 | 0.021 |
| DBP (mmHg) | 0.092 | 0.000 | 0.068 | 0.030 | 0.109 | 0.003 |
| ALT (IU/l) | 0.089 | 0.000 | 0.178 | 0.000 | 0.091 | 0.029 |
| AST (IU/l) | 0.179 | 0.000 | 0.199 | 0.000 | 0.172 | 0.000 |
| GGT (IU/l) | 0.190 | 0.000 | 0.281 | 0.000 | 0.131 | 0.002 |
| BUN (mmol/l) | 0.296 | 0.000 | 0.132 | 0.000 | 0.357 | 0.000 |
| SCR (μmol/l) | 0.410 | 0.000 | 0.361 | 0.000 | 0.373 | 0.000 |
| eGFR (ml/min per 1.73 m2) | −0.270 | 0.000 | −0.122 | 0.000 | −0.247 | 0.000 |
| TG (mmol/l) | 0.266 | 0.000 | 0.309 | 0.000 | 0.213 | 0.000 |
| TC (mmol/l) | 0.014 | 0.540 | 0.011 | 0.709 | −0.033 | 0.344 |
| HDL (mmol/l) | −0.155 | 0.000 | −0.184 | 0.000 | −0.155 | 0.000 |
| LDL (mmol/l) | 0.007 | 0.784 | −0.006 | 0.847 | −0.051 | 0.242 |
| VLDL (mmol/l) | 0.217 | 0.000 | 0.271 | 0.000 | 0.118 | 0.005 |
| HbA1c (%) | −0.109 | 0.000 | −0.115 | 0.000 | −0.036 | 0.320 |
| FPG (mmol/l) | −0.035 | 0.135 | −0.018 | 0.576 | −0.022 | 0.556 |
| P2hG (mmol/l) | −0.178 | 0.000 | −0.221 | 0.000 | −0.140 | 0.092 |
| FINS (mIU/l) | 0.225 | 0.000 | 0.218 | 0.000 | 0.219 | 0.010 |
| P2INS (mIU/l) | 0.206 | 0.000 | 0.207 | 0.000 | 0.170 | 0.052 |
| HOMA-IR | 0.190 | 0.000 | 0.177 | 0.000 | 0.187 | 0.031 |
| duration of diabetes (years) | 0.058 | 0.009 | 0.047 | 0.010 | 0.026 | 0.447 |
Abbreviations are as in Table 1.
In normal-glucose subjects in the physical examination population, SUA levels were positively correlated with BMI, both SBP and DBP, renal function (serum CR, BUN), blood lipid (TG), FBG, and glycated HbA1c (P-values < 0.05) and negatively correlated with eGFR and HDL (P-values < 0.05) (Table 4). We found no significant correlation between SUA and age. In T2DM subjects, SUA levels significantly positive correlated with BMI, DBP, renal function (serum CR, BUN), and blood lipid (TG; P-values < 0.05) and negatively correlated with eGFR, FBG, glycated HbA1c, and HDL (P-values < 0.05) (Table 4). We found no significant correlation between SUA,age, or SBP.
Table 4. Correlation analyses among serum uric acid and clinical characteristics in the physical examination population.
| Variable |
Normal glucose |
T2DM |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
All subjects |
eGFR normal |
eGFR abnormal |
All subjects |
eGFR normal |
eGFR abnormal |
|||||||
| rs | P | rs | P | rs | P | rs | P | rs | P | rs | P | |
| Age (years) | −0.015 | 0.335 | −0.134 | 0.000 | −0.040 | 0.048 | −0.064 | 0.207 | −0.302 | 0.000 | −0.062 | 0.319 |
| eGFR (ml/min per 1.73 m2) | −0.255 | 0.000 | −0.115 | 0.000 | −0.218 | 0.000 | −0.276 | 0.000 | −0.103 | 0.225 | −0.215 | 0.001 |
| BMI (kg/m2) | 0.329 | 0.000 | 0.369 | 0.000 | 0.308 | 0.000 | 0.206 | 0.000 | 0.254 | 0.009 | 0.171 | 0.013 |
| SBP (mmHg) | 0.107 | 0.000 | 0.098 | 0.000 | 0.071 | 0.001 | −0.015 | 0.783 | −0.008 | 0.934 | −0.065 | 0.338 |
| DBP (mmHg) | 0.166 | 0.000 | 0.212 | 0.000 | 0.158 | 0.000 | 0.106 | 0.004 | 0.273 | 0.003 | 0.013 | 0.846 |
| BUN (mmol/l) | 0.205 | 0.000 | 0.131 | 0.000 | 0.187 | 0.000 | 0.099 | 0.048 | 0.078 | 0.358 | 0.016 | 0.799 |
| SCR (μmol/l) | 0.483 | 0.000 | 0.467 | 0.000 | 0.484 | 0.000 | 0.330 | 0.000 | 0.307 | 0.000 | 0.258 | 0.000 |
| HbA1c (%) | 0.040 | 0.012 | 0.003 | 0.914 | 0.029 | 0.146 | −0.175 | 0.000 | −0.193 | 0.022 | −0.186 | 0.003 |
| FPG (mmol/l) | 0.084 | 0.000 | 0.098 | 0.000 | 0.069 | 0.001 | −0.131 | 0.009 | −0.034 | 0.692 | −0.200 | 0.001 |
| TG (mmol/l) | 0.325 | 0.000 | 0.391 | 0.000 | 0.284 | 0.000 | 0.289 | 0.000 | 0.373 | 0.000 | 0.249 | 0.000 |
| HDL (mmol/l) | −0.347 | 0.000 | −0.387 | 0.000 | −0.346 | 0.000 | −0.179 | 0.000 | −0.266 | 0.002 | −0.153 | 0.014 |
Abbreviations are as in Table 1.
To investigate effects of impaired renal function on uric acid phenotype correlations, we divided our cohort by normal (≥90 ml/min/1.73 m2) and abnormal (<90 ml/min/1.73 m2) eGFR. Most correlations listed in Tables 3 and 4 were relatively unchanged with normal eGFR.
Multivariate Analyses
We carried out binary logistic analyses to assess the relationship between HbA1c/FPG and HUA. In the multivariate models, the presence of HUA was a dependent parameter. Independent parameters were associated with the presence of HUA in univariate analysis with a p value of <0.05 (Tables 5 and 6). All the independent parameters were pooled together in the analysis, and adjusted ORs were calculated with the stepwise method.
Table 5. Odds ratio of HbA1c for incidence of hyperuricemia, and stepwise logistic regression for hyperuricemia.
| Population [N (%)] | Odds ratio | 95% CI | P-value |
|---|---|---|---|
| T2DM subjects [388 (17.24%)] | |||
| Model1a | 0.886 | 0.825~0.952 | 0.001 |
| Model2b | 0.897 | 0.833~0.965 | 0.003 |
| Model3c | 0.988 | 0.981~0.995 | 0.001 |
| Physical examination population | |||
| Normal glucose [556 (15.67%)] | |||
| Model4a | 1.352 | 1.101~1.662 | 0.004 |
| Model5b | 1.229 | 0.974~1.551 | 0.082 |
| Model6d | 1.030 | 0.786~1.350 | 0.828 |
| T2DM subjects [160 (18.37%)] | |||
| Model7a | 0.626 | 0.434~0.902 | 0.012 |
| Model8b | 0.650 | 0.462~0.914 | 0.013 |
| Model9e | 0.722 | 0.539~0.968 | 0.029 |
*P < 0.05 was considered statistically significant.
aUnadjusted baseline values of HbA1c.
bAdjusted for age and sex.
cFurther adjusted for duration of diabetes, BMI, SBP, AST, eGFR, BUN, SCR, TG, TC, VLDL, FINS, P2INS, HOMA-IR. (see Table 1 for abbreviations).
dFurther adjusted for eGFR, BMI, SBP, DBP, BUN, SCR, FBG, TG, HDL.
eFurther adjusted for eGFR, BMI, BUN, SCR, FBG, TG.
Table 6. Odds ratio of FPG for incidence of hyperuricemia, and stepwise logistic regression for hyperuricemia.
| Population [N (%)] | Odds ratio | 95% CI | P-value |
|---|---|---|---|
| T2DM subjects [388 (17.24%)] | |||
| Model1a | 0.983 | 0.937~1.030 | 0.468 |
| Model2b | 0.987 | 0.941~1.035 | 0.584 |
| Model3c | 1.062 | 0.931~1.212 | 0.373 |
| Physical examination population | |||
| Normal glucose [556 (15.67%)] | |||
| Model4a | 1.328 | 1.067~1.654 | 0.011 |
| Model5b | 1.008 | 1.001~1.014 | 0.016 |
| Model6d | 1.020 | 0.499~2.085 | 0.956 |
| T2DM subjects [160 (18.37%)] | |||
| Model7a | 0.986 | 0.973~0.999 | 0.030 |
| Model8b | 0.971 | 0.949~0.993 | 0.011 |
| Model9e | 0.610 | 0.419~0.887 | 0.010 |
*P < 0.05 was considered statistically significant.
aUnadjusted baseline values of FPG.
bAdjusted for age and sex.
cFurther adjusted for duration of diabetes, HbA1c, BMI, SBP, AST, eGFR, BUN, SCR,TG, TC, VLDL, FINS, P2INS, HOMA-IR.
dFurther adjusted for eGFR, BMI, SBP, DBP, BUN, SCR, HbA1c, TG, HDL.
eFurther adjusted for eGFR, BMI, BUN, SCR, HbA1c, TG.
At baseline, in an unadjusted model (Table 5, models 1 and 7), HbA1c was negatively correlated with HUA both in T2DM patients and the physical examination population (T2DM). Hazard ratios for HUA were 0.866 (95% CI, 0.825~0.952) and 0.626 (95% CI, 0.434~0.902), respectively; after adjusting for age and gender (Table 5, models 2 and 8), they were 0.897 (95% CI, 0.833~0.965) and 0.650 (95% CI, 0.462~0.914), respectively. The negative association was also significant after further adjustment for multiple metabolic parameters (Table 5, models 3 and 9), with hazard ratios of 0.872 (95% CI, 0.790~0.963) and 0.722 (95% CI, 0.539~0.968), respectively (P < 0.05). In normal-glucose subjects in the physical examination population, the presence of HUA was positively associated with HbA1c. In an unadjusted model (Table 5, model 4), the hazard ratio for HUA was 1.352 (95% CI, 1.101~1.662), but in the adjustment models (Table 5, models 5 and 6), the positive association no longer existed.
In the physical examination population (T2DM), FPG was negatively correlated with HUA (Table 6, models 7). Hazard ratios for HUA were 0.986 (95% CI, 0.973~0.999). After adjusting for age, gender (Table 6, models 8) and multiple metabolic parameters (Table 6, models 9), the negative association was also significant, with hazard ratios of 0.971 (95% CI, 0.949~0.993) and 0.610 (95% CI, 0.419~0.887), respectively (P < 0.05).
Genetic association studies
We carried out association studies among single nucleotide polymorphisms (SNPs) of glucose-uric acid transporter genes and SUA levels in 2250 T2DM patients. Alleles of two glucose-uric acid transporter genes, ABCG2 (rs2231142) and SLC2A9 (rs7660895 and rs1014290), were significantly associated with SUA (P < 0.05; Table 7). The CC genotype of rs2231142, the AA genotype of rs7660895, and the CC genotype of rs1014290 were associated with lower SUA levels than their counterpart alleles.
Table 7. Candidate gene association studies for SUA.
| gene | genotype | SUA (μmol/l) | *P-value(allele) | #P-value(genotype) |
|---|---|---|---|---|
| ABCG2 (rs2231142) | CC | 295.0 ± 117.2 | 0.0005 | 0.000 |
| CA | 322.1 ± 122.8 | |||
| AA | 323.7 ± 121.5 | |||
| SLC2A9 (rs7660895) | GG | 309.6 ± 115.8 | 0.0438 | 0.039 |
| AG | 309.3 ± 127.1 | |||
| AA | 301.2 ± 116.3 | |||
| SLC2A9 (rs1014290) | TT | 311.6 ± 114.0 | 0.0244 | 0.040 |
| CT | 307.2 ± 126.8 | |||
| CC | 293.1 ± 118.2 |
*P-value: quantitative association study between serum uric acid levels with alleles of two glucose-uric acid transporter genes, ABCG2 (rs2231142) and SLC2A9 (rs7660895 and rs1014290). #P-value: comparison of serum uric acid levels among different genotypes.
Discussion
Currently, gout and renal disorders were considered main consequences of HUA, and SUA is recognized as a potential risk factor for hypertension, stroke, and CVDs9. A large number of studies have linked HUA with hypertension, CVD, and T2DM. An SUA increase of 59.5 μmol/ results in a 60% increase in risk for developing T2DM10. The present study demonstrated that HUA prevalence in a physical examination population was 16.20% (men, 17.67%; women, 12.02%) and in T2DM patients was 17.24% (men, 14.86%; women, 20.06%). Qiu et al. reported that an HUA prevalence level of 13.7% (21.1% in men and 7.9% in women) in two northern provinces of China11. The adjusted prevalence of HUA among Chinese adults in 2009~2010 was 8.4% (men, 9.9%; women, 7.0%)12. Compared with these results, our study population had a higher prevalence of HUA.
The prevalence of diabetes has been increasing worldwide, and the total number of people with diabetes has been projected to rise from 94 million in 2003 to 333 million in 202513. Elevated SUA levels predict the onset of T2DM. Approximately 1 in 11 cases of new T2DM and approximately 8.7% of all new cases of T2DM were statistically attributed to HUA14,15. Ogbera et al. reported a 25% prevalence of HUA in Nigerian patients with T2DM. SUA increases with age and may occur more in women, especially after attainment of menopause16. Among Chinese T2DM patients with central obesity, HUA prevalence was 36.1% in women and 28.4% in men17.
Glycated HbA1c is widely used as a clinical parameter of chronic glycemic control. HbA1c is an easily determined measure of mean glucose level over the previous 2~3 months and is the recommended method for assessing the effectiveness of therapies15. HbA1c has been proposed as a diagnostic tool to identify people with undiagnosed T2DM or who are at risk of T2DM. HbA1c does not require fasting, has better pre-analytical stability, and reflects long-term glycemic exposure better than do current diagnostic tests based on fasting or post load glucose measures18. One of the interesting findings of our present study is the inverse association of SUA with diabetic parameters (HbA1c, FPG). The T2DM subjects showed a negative association between SUA and HbA1c (P = 0.000). The T2DM subjects in the physical examination population showed a negative association between SUA with FBG (P = 0.009) and HbA1c (P = 0.000). In contrast, normal glucose subjects in the physical examination population showed a positive association between SUA with FBG (P = 0.000) and glycated HbA1c (P = 0.012). Multivariate analyses showed that HUA was significantly associated with low HbA1c both in T2DM subjects (OR = 0.872, 95% CI: 0.790~0.963) and in the physical examination population (T2DM) (OR = 0.722, 95% CI: 0.539~0.968).
Nan H. et al. reported that SUA levels tended to increase with increasing FPG levels in non-diabetic individuals but decreased in diabetic individuals3. In a nationally representative sample of US men and women, SUA levels and the frequency of HUA increased with moderately increasing levels of HbA1c (6~6.9%) and then decreased with further increasing levels of HbA1c (a bell-shaped relation); SUA levels showed a similar bell-curved relation with FBG, and there was a positive association between SUA and HbA1c levels <7% but an inverse association between SUA and T2DM (or HbA1c ≥ 7%)19. Wang et al. found that the risk of HUA decreased 0.928-fold for every 1% increase in HbA1c and 0.962-fold for every 1 mmol/l increase in FPG17. Li et al. reported that SUA was negatively correlated with HbA1c (correlation coefficient = −0.24, p < 0.001) and FPG levels (correlation coefficient = −0.26, p < 0.001) in patients with T2DM4. But Fan et al. found that SUA in individuals with IFG and/or IA1c was positive associated with 2-h PG, independent of FPG and HbA1c, the result was somewhat contrary to our findings9. The inverse relationship between SUA and diabetic parameters (HbA1c, FPG) observed in these diabetic subjects may be caused by increased renal excretion of uric acid in the presence of hyperglycemia. It is well known that with increasing duration of diabetes, which is accompanied by worsening of beta cell function and deterioration of glycemic control, the rate of renal filtration increases gradually. The hyperfiltration state caused by hyperglycemia promotes the excretion of uric acid, which partly explains the inverse relationship between SUA and diabetic parameters4.
Mechanisms that relate SUA to T2DM are still unclear, but several have been suggested. Animal experiments have shown that HUA may induce endothelial dysfunction by inhibiting nitric oxide (NO) bioavailability. Because insulin depends on NO for stimulation of glucose uptake, this may result in inhibited glucose uptake. Therefore, HUA may play an important role in the development or worsening of insulin resistance. Furthermore, a direct effect on adipocytes has been suggested: in mouse adipocytes, uric acid induced a proinflammatory state20.
The positive SUA-FPG (and HbA1c) correlation in normal individuals and the inverse correlation in T2DM patients suggested a regulatory SUA mechanism that coupled with FPG levels. Indeed, gene polymorphisms of two hexose-uric acid transporters in renal tubules (SLC2A9 and ABCG2) are associated with HUA in genome-wide association studies21,22. We further genotyped SLC2A9 and ABCG2 gene polymorphisms in our populations, results showed that individuals with different SLC2A9 and ABCG2 genotypes indeed had different SUA levels. Our study showed the associations between SUA level and SNPs in ABCG2 and SLC2A9 in Chinese Han T2DM patients. Alleles rs7660895 and rs1014290 of the SLC2A9 gene and rs2231142 of the ABCG2 gene were significantly associated with SUA levels (P < 0.05). The CC genotype of rs2231142, the AA genotype of rs7660895, and the CC genotype of rs1014290 were associated with lower uric acid levels than their counterpart alleles. Recently, Giri et al. found that SLC2A9 and ABCG2 gene variants were associated with SUA level in Indians, differences in effect sizes of SLC2A9 and ABCG2 polymorphisms were observed between healthy subjects and type 2 diabetes patients23. Liu et al. showed that the SLC2A9 gene SNP rs1014290 was associated with the decreased risk of type 2 diabetes, serum glucose level, and SUA in Han Chinese24. SLC2A9 and ABCG2 are most strongly associated with regulating SUA concentration. ABCG2 contributes not only to renal urate excretion but also to gut urate excretion via intestinal and biliary secretion in humans25. SLC2A9 was a transporter for both fructose and urate. Yang et al. reported that the loci of ABCG2 and SLC2A9 could explained 1.09% and 1.03% of the variation of SUA levels respectively26.
For those individual with impaired renal function (eGFR decreased, Table 3), the correlation between SUA and FPG vanished, it also suggested the glucose-uric acid coupling might dependent on hexose-uric acid transporters at proximal renal tubules. Like the regulation of the blood glucose, the SUA level might be precisely adjusted via the renal uric acid-hexose transporters. The increased SUA might be an early signal of insulin resistance, the inverse correlation between SUA and HbA1c (FPG) continues until the renal function was severely damaged by diabetic nephropathy.
Materials and Methods
Participants
We recruited 2,250 unrelated Han Chinese T2DM patients in Tianjin, China (2011~2014). Diabetes mellitus was defined upon World Health Organization criteria (fasting plasma glucose ≥ 7.0 mmol/L, and/or 2-h oral glucose tolerance tests (OGTT) ≥ 11.1 mmol/L), or the use of anti-diabetic medicine. All the subjects were unrelated Han Chinese receiving treatment at the Metabolic Disease Hospital of Tianjin Medical University, the General Hospital of Tianjin Medical University, the Tianjin People’s Hospital, and the Eye Hospital of Tianjin Medical University. We have also collected 4,420 Han Chinese subjects from a physical examination population in 2014: 871 were T2DM patients (fasting plasma glucose ≥ 7.0 mmol/L) and 3549 had normal fasting plasma glucose (FPG) levels (fasting plasma glucose < 6.1 mmol/L). Subject recruiting protocols were reviewed and approved by the Human Ethics Committee of Tianjin Medical University. Subjects gave written informed consent prior to participating in this study. All experiments were performed in accordance with relevant guidelines and regulations.
Measurement
All subjects were measured twice for height and weight (using identical standardized anthropometric scales), and body mass index (BMI) was calculated (kg/m2). Diabetes mellitus was defined upon World Health Organization criteria (fasting plasma glucose ≥ 7.0 mmol/L, and/or 2-h oral glucose tolerance tests (OGTT) ≥ 11.1 mmol/L), or the use of anti-diabetic medicine. Fasting blood samples were drawn after 12 h of fasting followed by an OGTT (75 g glucose were given) to evaluate glucose tolerance status and OGTT-related insulin release (samples for measurement of plasma glucose and serum insulin were drawn at 0, 30, 90 and 120 min). Fasting plasma glucose (FPG), plasma glucose 120 min post- OGTT (P2hG), fasting serum insulin (FINS), serum insulin 120 min post-OGTT (P2INS) were collected. SUA levels were measured by enzymatic methods (Chemistry Analyzer Au2700, Olympus Medical Engineering Company, Japan). Blood pressure (BP) was measured by a physician using a mercury sphygmomanometer, and hypertension was defined as systolic BP (SBP) at least 140 mmHg and/or diastolic BP (DBP) at least 90 mmHg, and/or use of antihypertension medication. Total cholesterol (TC), high-density- lipoprotein cholesterol (HDL), low-density-lipoprotein cholesterol (LDL), triglycerides (TG), serum creatinine (SCR), blood urea nitrogen (BUN), galactosyl glucosyltransferase (GGT), alanine aminotransferase (ALT), Aspartate transaminase (AST) and glycated hemoglobin (HbA1c) were measured using the Sysmex Chemix-180 automatic biochemical analysis device (Sysmex Infosystems, Kobe, Japan). Insulin was measured by an enzymatic luminescence technique. HUA was defined as an SUA concentration ≥ 420 μmol/l in men and ≥360 μmol/l in women27. Values of estimated glomerular filtration rate (eGFR; ml/min/1.73 m2) were calculated by using the equation proposed by investigators in the Chronic Kidney Disease Epidemiology Collaboration28. Insulin resistance was estimated using the homeostasis model assessment index-insulin resistance (HOMA-IR): HOMA-IR = [fasting insulin (μIU/ml) × fasting glucose (mmol/l)]/22.529.
Genotyping for glucose-uric Acid transporter genes
We carried out association studies among single nucleotide polymorphism (SNPs) of two renal tubular glucose-uric acid transporter genes, SLC2A9 and ABCG2, and serum uric acid levels. Genomic DNA samples were extracted from peripheral whole blood samples using the high-salt method. We selected 3 candidate SNPs from SLC2A9 (rs13129697, rs7660895, rs1014290) and 1 candidate SNPs from ABCG2 (rs2231142), genotyping was performed by primer extension of multiplex products with detection by matrix-assisted laser desorption time-of-flight mass spectrometry.
Statistical analysis
The basic characteristics of the sample were described by descriptive statistics. The clinical characteristics between normal and HUA groups were analyzed using the non-parametric test in the continuous variables. The chi-square test was used to compare the differences in percentages in the dichotomous variables. Spearman’s correlation coefficients were calculated to describe the association between variables. A non-conditional logistic regression model was used to examine which variables were statistically significant risk factors in certain groups in relation to and adjusted for the relevant confounders using bivariate analysis. Odds ratio (OR) and 95% confidence interval (CI) for HUA were calculated. For statistical inference, a bilateral P-value of <0.05 was considered statistically significant. All statistical analyses were carried out using SPSS statistical software, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows. All phenotypes were documented in a Filemaker Pro database. An association analysis was performed using PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/). We also compared the SUA levels between different genotypes by ANOVA (SPSS Inc., Chicago, IL, USA).
Conclusions
We have found that SUA level is inversely associated with HbA1c in T2DM patients but positively correlated with HbA1c in normal-glucose subjects. Genetic association studies in T2DM patients showed that two glucose-uric acid transporter genes, ABCG2 and SLC2A9, were significantly associated with SUA in T2DM patients. In those individuals with impaired renal function, the SUA-FPG coupling vanished. Seems the reverse transporting of uric acid and glucose in renal tubules might be accounted for the associations between SUA and HbA1c, the SUA-T2DM association needs a reappraisal in the future epidemiology studies. Additional attention should be given to healthy lifestyles and early interventions to control obesity and lipid abnormalities, to effectively reduce HUA risk and avoid the occurrence of gout. In future research, we plan to investigate clinical outcomes of individuals with elevated SUA levels in our cohort and to test genetic backgrounds related to HUA in general populations.
Additional Information
How to cite this article: Wei, F. et al. Serum Uric Acid Levels were Dynamically Coupled with Hemoglobin A1c in the Development of Type 2 Diabetes. Sci. Rep. 6, 28549; doi: 10.1038/srep28549 (2016).
Acknowledgments
We thank all subjects who took part in this study. This study was supported by National Natural Science Foundation of China grants 81070576 (W.-D.L.), 81072922 (L.C.), 71473175 (Y.G.W.), 71273187 (Y.G.W.), and by grant 12JCZDJC24700 from Tianjin Municipal Science and Technology Commission (W.-D.L.), grant 15ZCZDSY00500 from Tianjin Key Project of Scientific Support to Y.G.W. We thank all of the patients for their cooperation and also the clinical doctors of Metabolic Diseases Hospital.
Footnotes
Author Contributions W.-D.L., L.C. and Y.W. conceived and designed the study; W.-D.L. and F.W. wrote the manuscript; W.-D.L., F.W., B.C., X.Y., Y.W. performed the experiments; F.W. and X.Y. analyzed the data; B.C. and L.C. collected subjects and clinical data. All authors have reviewed the manuscript.
References
- Kim T. H. et al. The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus. Diabetol Metab Syndr 4, 3, 10.1186/1758-5996-4-3 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gosling A. L., Matisoo-Smith E. & Merriman T. R. Hyperuricaemia in the Pacific: why the elevated serum urate levels? Rheumatol Int 34, 743–757, doi: 10.1007/s00296-013-2922-x (2014). [DOI] [PubMed] [Google Scholar]
- Nan H. et al. Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract 76, 68–74 (2007). [DOI] [PubMed] [Google Scholar]
- Li Q. et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 10, 72, 10.1186/1475-2840-10-72 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Taniguchi Y. et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 19, 1209–15 (2001). [DOI] [PubMed] [Google Scholar]
- Guan M. & Zhou D. Association of an intronic SNP of SLC2A9 gene with serum uric acid levels in the Chinese male Han population by high-resolution melting method[J]. Clin Rheumatol 30, 29–35, 10.1007/s10067-010-1597-x (2011). [DOI] [PubMed] [Google Scholar]
- Sun X. et al. Serum uric acid levels are associated with polymorphisms in the SLC2A9, SF1, and GCKR genes in a Chinese population[J]. Acta Pharmacol Sin 35, 1421–7, 10.1038/aps.2014.87 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhou D. et al. Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population. Int J Mol Sci 15, 9149–59, 10.3390/ijms15059149 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fan H. Q. et al. Association of Serum Uric Acid with 2-Hour Postload Glucose in Chinese with Impaired Fasting Plasma Glucose and/or HbA1c. Plos. one 8, e67759, 10.1371/journal.pone.0067759 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vučak J. et al. Association between hyperuricemia, prediabetes, and prehypertension in the Croatian adult population–a cross-sectional study. BMC Cardiovasc Disord 12, 117, 10.1186/1471-2261-12-117 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qiu L. et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health 13, 664, 10.1186/1471-2458-13-664 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu H. et al. Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol. [Epub ahead of print] (2014). [DOI] [PubMed] [Google Scholar]
- Miyake T. et al. Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One 9, e107882, 10.1371/journal.pone.0107882 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krishnan E. et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM 106, 721–9, 10.1093/qjmed/hct093 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Engoren M., Schwann T. A. & Habib R. H. Elevated hemoglobin A1c is associated with readmission but not complications. Asian Cardiovasc Thorac Ann 22, 800–806, 10.1177/0218492313515895 (2014). [DOI] [PubMed] [Google Scholar]
- Ogbera A. O. & Azenabor A. O. Hyperuricaemia and the metabolic syndrome in type 2 DM. Diabetol Metab Syndr 2, 24, 10.1186/1758-5996-2-24 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang J. et al. Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China. Asia Pac J Clin Nutr 22, 590–598, 10.6133/apjcn.2013.22.4.16 (2013). [DOI] [PubMed] [Google Scholar]
- Su X. et al. Hemoglobin A1c for diagnosis of postpartum abnormal glucose tolerance among women with gestational diabetes mellitus: diagnostic meta-analysis. Plos One 9, e102144, 10.1371/journal.pone.0102144 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Choi H. K. & Ford E. S. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels–the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 47, 713–717, 10.1093/rheumatology/ken066 (2008). [DOI] [PubMed] [Google Scholar]
- Sluijs I. et al. Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr 143, 80–85, 10.3945/jn.112.167221 (2013). [DOI] [PubMed] [Google Scholar]
- Dehghan A. et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372, 1953–1961, 10.1016/S0140-6736(08)61343-4 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Döring A. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40, 430–436, 10.1038/ng.107 (2008). [DOI] [PubMed] [Google Scholar]
- Giri A. K. et al. Genome wide association study of uric acid in Indian population and interaction of identified variants with Type 2 diabetes. Sci Rep 6, 21440, 10.1038/srep21440 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu W. C. et al. The rs1014290 polymorphism of the SLC2A9 gene is associated with type 2 diabetes mellitus in Han Chinese. Exp Diabetes Res 527520, 10.1155/2011/527520 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsuo H. et al. ABCG2/BCRP dysfunction as a major cause of gout. Nucleosides Nucleotides Nucleic Acids 30, 1117–1128, 10.1080/15257770.2011.633954 (2011). [DOI] [PubMed] [Google Scholar]
- Yang B. et al. A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population. BMC Med Genomics 7, 10, 10.1186/1755-8794-7-10 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang Y. et al. Risk factors for gout developed from hyperuricemia in China: a five-year prospective cohort study. Rheumatol Int 33, 705–710, 10.1007/s00296-012-2439-8 (2013). [DOI] [PubMed] [Google Scholar]
- Levey A. S. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150, 604–612 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vayá A. et al. Association of metabolic syndrome and its components with hyperuricemia in a Mediterranean population. Clin Hemorheol Microcirc 60, 327–34, 10.3233/CH-141887 (2015). [DOI] [PubMed] [Google Scholar]